Crossmark

Predictable and precise template-free CRISPR editing of pathogenic variants

Crossref DOI link: https://doi.org/10.1038/s41586-018-0686-x

Published Online: 2018-11-07

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shen, Max W.

Arbab, Mandana

Hsu, Jonathan Y.

Worstell, Daniel

Culbertson, Sannie J.

Krabbe, Olga

Cassa, Christopher A.

Liu, David R.

Gifford, David K.

Sherwood, Richard I.
License Information

Text and Data Mining valid from 2018-11-01
More Information

Article History

Received: 27 April 2018

Accepted: 10 September 2018

First Online: 7 November 2018

Change Date: 14 February 2019

Change Type: Correction

Change Details: In this Article, a data processing error affected Fig. 3e and Extended Data Table 2; these errors have been corrected online.

Competing interests

: The authors declare competing interests: patent applications have been filed on this work. D.R.L. is a consultant and co-founder of Editas Medicine, Beam Therapeutics and Pairwise Plants, companies that use genome editing technologies. D.K.G. is a co-founder of Think Therapeutics, a company that uses machine learning for therapeutic development.